Significant Ownership of Julian C. Baker
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Julian C. Baker focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager location
- New York, NY
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
1 identity field
Follow Filing Activity
Follow Julian C. Baker and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Julian C. Baker
Significant Ownership of Julian C. Baker
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 25% | $1,162,886,859 | 43,294,373 | Julian C. Baker | 24 Feb 2026 | ||
| ONC | BeOne Medicines Ltd. (f/k/a BeiGene Ltd.) | Ordinary Shares, par value $0.0001 per share | 8% | $34,424,296,187 | 115,918,313 | Julian C. Baker | 16 Apr 2026 | ||
| KNSA | Kiniksa Pharmaceuticals International, plc | Class A Ordinary Shares, nominal value $0.000273235 per share | 7% | $140,056,330 | 3,253,341 | Julian C. Baker | 21 May 2026 |
Schedules 13D/G Reported by Julian C. Baker:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.